The FDA’s Suzanne Schwartz said at The Medtech Conference that addressing legacy devices is a “work in progress” and a problem that regulators and industry need to work on together.

RBC Capital raised the firm’s price target on Johnson & Johnson to $181 from $178 and keeps an Outperform rating on the ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the first phase of launching its Volt Variable Angle Optimized Locking ...

Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), retaining the price ...

Operator Good morning and welcome to Johnson & Johnson's third quarter 2024 earnings conference call. All participants will ...

The company also revised its operational earnings forecast from $10.05 to $9.91. The V-Wave acquisition is expected to dilute ...

Matt Miksic, an analyst from Barclays, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated price ...

TORONTO—While the FDA has already doled out green lights to about 950 medical devices backed by artificial intelligence or ...

Johnson & Johnson’s medtech acquisitions over the past year have fueled growth for its cardiovascular group, offsetting challenges in businesses like orthopedics and surgery.

Sales of Johnson & Johnson’s oncology drugs jumped nearly 19% in the third quarter, driven by cancer treatment Darzalex which ...